Image Credit: Adobe Stock Images/Ven.com
Merck KGaA, Darmstadt, Germany, a science and technology company, recently launched a beta version of M-Trust, a secure cyber-physical trust platform, which has been designed to address issues pertaining to product safety, traceability and counterfeiting, issues that pose as challenges to the life science industry.1
M-Trust reportedly allows companies to boost their product quality and authenticity by connecting the physical and digital spheres. The platform as a service (PaaS) offering is run by Web 3.0 technology, while allowing for the design of digital twins, which is where the additional product security and process digitization comes in.
“As expectations for product quality control rise, companies must ensure safety and transparency in their industrial value chains while complying with ever-tightening regulations,” explained Laura Matz, the company’s chief science & technology officer. “Until now, they may have struggled to fully digitalize assurance processes because machines did not meet human standards. M-Trust is a first-to-market, cyber-physical trust platform that enhances product traceability and authenticity by digitally empowering human capabilities in quality control processes. Designed for businesses that want to remain competitive in today’s connected world, this innovative technology is also poised to enable the novel business models of tomorrow.”
More specifically, the program allows customers operate within a framework that allows them to create digital systems that convert quality control human capabilities into “more efficient and less error-prone” machine-to-machine interactions, which helps machines accurately recognize objects and make certifiable claims.
M-Trust also assists with integrating product authenticity into their systems, and utilizing crypto anchor tech to connect physical products to their digital identities, which boosts supply chain traceability and quality assurances.
In other Merck KGaA news, the company’s life science business—MilliporeSigma—purchased HUB Organoids B.V. (HUB) late last year.2 The acquisition, noted that company, is a “strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for faster and more effective drug development.”
And in April 2024, the science and tech business announced that it will be financially committing more than $322 million (€300 million) into a brand-new, 18,000 square-foot research center at its global HQ in Darmstadt, Germany.3
Known as the “Advanced Research Center,” the company’s life science business branch plans on exploring solutions surrounding mRNA applications and manufacturing antibodies, along with products needed required for biotechnological production. By the start of 2027, it is anticipated to provide enough space for around 550 employees.
“Investments such as those made by Merck KGaA, Darmstadt, Germany, here at its headquarters in Darmstadt make tremendous economic, medical and scientific sense,” said Federal Chancellor Olaf Scholz. “They are a tribute to Germany as a leading pharmaceutical, industrial, and research location, and reflect the strength of the life sciences. All of this proves that we are on the right track with the changes that we have made with a view to offering the pharmaceutical and biotech industry better conditions. The German government will continue to tread this path with all due resolve.”
References
1. Merck KGaA, Darmstadt, Germany, launches first-to-market, cyber-physical trust platform to tackle issues of product safety and counterfeiting. PR Newswire. January 6, 2025. Accessed January 9, 2025. https://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-launches-first-to-market-cyber-physical-trust-platform-to-tackle-issues-of-product-safety-and-counterfeiting-302341944.html?tc=eml_cleartime
2. MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio. Merck KGaA. January 6, 2025. Accessed January 9, 2025. https://www.emdgroup.com/en/news/hub-close-06-01-2025.html
3. Saraceno N. Merck KGaA Financially Commits $322 Million Toward Research Center. Pharmaceutical Commerce. January 6, 2025. Accessed January 9, 2025. https://www.pharmaceuticalcommerce.com/view/merck-kgaa-financially-commits-322-million-toward-research-center